Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib

Phase 3

Completed

• Conditions: Whole Cell Pertussis; Tetanus; Diphtheria; Hepatitis B; Haemophilus Influenzae Type b
• Interventions: Biological: Tritanrix™-HepB/Hiberix™; Biological: DTPw-HBV/Hib Kft vaccine GSK323527A

• Registration Number: NCT00332566
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This booster study will assess the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine versus DTPw-HBV/Hib vaccine, in healthy children, 18 to 24 months of age, who received the same vaccine for primary vaccination. Prior to the booster dose, this study will also assess the persistence of antibodies to the vaccine antigen components administered in the primary vaccination course. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-05-31
• Study First Submitted QC: 2006-05-31
• Study Start: 2006-06
• Study First Posted: 2006-06-01
• Primary Completion: 2006-10
• Study Completion: 2006-10
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-27
• Last Update Posted: 2016-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 148

Inclusion Criteria

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• A male or female toddler, 18 to 24 months of age at the time of booster vaccination, who completed the three-dose primary vaccination course in the 101223 study.
• Written informed consent obtained from the parent or guardian of the subject.
• Healthy subjects as established by medical history and clinical examination before entering into the study.

Read More

Exclusion Criteria

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the booster dose of study vaccine, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.

• Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before and ending 30 days after administration of the booster vaccine dose, with the exception of oral polio vaccine (OPV).

• Previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis B and Hib disease since the conclusion visit of the 101223 study.

• History of diphtheria, tetanus, pertussis, hepatitis B and Hib disease.

• Known exposure to diphtheria, tetanus, pertussis, hepatitis B and Hib disease since the conclusion visit of the 101223 study.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).

• Major congenital defects or serious chronic illness.

• History of any neurologic disorders or seizures.

• Acute disease at the time of enrolment.

• Administration of immunoglobulins and/or any blood products during the study period.

• Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.

• One of the following adverse events that constitute absolute contraindications to further administration of DTP vaccine, having occurred after previous administration of DTPw vaccine.

  • Known hypersensitivity to any component of the vaccine, or having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis or HB vaccines.
  • Encephalopathy
  • Axillary temperature of >= 40 °C/ rectal temperature >= 40.5 °C within 48 hours of vaccination.
  • Collapse or shock-like state within 48 hours of vaccination.
  • Persistent, inconsolable crying lasting >= 3 hours occurring within 48 hours of vaccination.
  • Seizures with or without fever occurring within 3 days of vaccination.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B	Tritanrix™-HepB/Hiberix™	-
Group A	DTPw-HBV/Hib Kft vaccine GSK323527A	-

Primary Outcome Measures

Name	Time	Method
Anti-tetanus antibody concentration	One month after the booster dose
Anti-polyribosyl-ribitol-phosphate (PRP) antibody concentration	One month after the booster dose
Anti-diphtheria antibody concentration	One month after the booster dose
Anti-hepatitis B surface antigen (HBs) antibody concentration	One month after the booster dose

Secondary Outcome Measures

Name	Time	Method
Anti-BPT antibody concentration	Prior to the booster dose
Occurrence of solicited symptoms	During the 4-day follow-up period after the booster dose
Anti-HBs antibody concentration	Prior to the booster dose
Occurrence of serious adverse events	During the entire study period.
Anti-Bordetella pertussis (BPT) antibody concentration	One month after the booster dose
Anti-PRP antibody concentration	Prior to the booster dose
Anti-diphtheria antibody concentration	Prior to the booster dose
Anti-tetanus antibody concentration	Prior to the booster dose
Occurrence of unsolicited symptoms	During the 31-day follow-up period after the booster dose

Trial Locations

Locations (1)

GSK Investigational Site; 🇳🇮 Leon, Nicaragua